SRPT

18.10

1.74% -0.32

Handel nachbörslich: 17.78 -0.32 -1.77%

Sarepta Therapeutics Inc (SRPT)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt SRPT? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$18.42

Offen:

$18.22

24-Stunden-Volumen:

1.56M

Relative Volume:

0.47

Marktkapitalisierung:

$1.91B

Einnahmen:

$2.18B

Nettoeinkommen (Verlust:

$-64.32M

KGV:

-18.77

EPS:

-0.9641

Netto-Cashflow:

$91.18M

1W Leistung:

+7.87%

1M Leistung:

+0.78%

6M Leistung:

+1.74%

1J Leistung:

-10.84%

1-Tages-Spanne:

$17.69

$18.26

1-Wochen-Bereich:

$16.38

$18.73

52-Wochen-Spanne:

$14.68

$25.32

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Firmenname

Sarepta Therapeutics Inc

Sektor

Healthcare (1080)

Branche

Biotechnology (604)

Telefon

617-274-4000

Adresse

215 FIRST STREET, CAMBRIDGE, MA

Mitarbeiter

835

Twitter

@sarepta

Nächster Verdiensttermin

2026-08-05

Neueste SEC-Einreichungen

SRPT's Discussions on Twitter

Compare SRPT vs VRTX, REGN, ARGX, RVMD, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SRPT Sarepta Therapeutics Inc	18.10	1.94B	2.18B	-64.32M	91.18M	-0.9641
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-28	Fortgesetzt	Barclays	Equal Weight
2025-12-09	Eingeleitet	Wedbush	Outperform
2025-11-05	Hochstufung	Mizuho	Neutral → Outperform
2025-09-22	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2025-07-29	Hochstufung	Barclays	Underweight → Equal Weight
2025-07-29	Eingeleitet	Bernstein	Mkt Perform
2025-07-29	Bestätigt	H.C. Wainwright	Sell
2025-07-29	Hochstufung	JP Morgan	Underweight → Neutral
2025-07-29	Hochstufung	Oppenheimer	Perform → Outperform
2025-07-28	Herabstufung	Barclays	Equal Weight → Underweight
2025-07-25	Herabstufung	JP Morgan	Neutral → Underweight
2025-07-24	Eingeleitet	Citigroup	Sell
2025-07-23	Herabstufung	BofA Securities	Neutral → Underperform
2025-07-22	Herabstufung	Barclays	Overweight → Equal Weight
2025-07-21	Herabstufung	Deutsche Bank	Buy → Hold
2025-07-21	Herabstufung	Leerink Partners	Outperform → Market Perform
2025-07-21	Herabstufung	Mizuho	Outperform → Neutral
2025-07-21	Herabstufung	Needham	Hold → Underperform
2025-07-21	Herabstufung	UBS	Buy → Neutral
2025-07-18	Herabstufung	Needham	Buy → Hold
2025-06-20	Herabstufung	William Blair	Outperform → Mkt Perform
2025-06-18	Herabstufung	TD Cowen	Buy → Hold
2025-06-17	Eingeleitet	Wolfe Research	Peer Perform
2025-06-16	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2025-06-16	Herabstufung	BofA Securities	Buy → Neutral
2025-06-16	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2025-06-16	Herabstufung	H.C. Wainwright	Neutral → Sell
2025-06-16	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-06-16	Herabstufung	Piper Sandler	Overweight → Neutral
2025-06-06	Hochstufung	Scotiabank	Sector Perform → Sector Outperform
2025-05-08	Herabstufung	Evercore ISI	Outperform → In-line
2025-04-11	Eingeleitet	Wells Fargo	Overweight
2025-04-02	Hochstufung	H.C. Wainwright	Sell → Neutral
2025-03-31	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-02-11	Eingeleitet	Deutsche Bank	Hold
2024-11-27	Bestätigt	Needham	Buy
2024-11-25	Eingeleitet	H.C. Wainwright	Sell
2024-11-07	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2024-10-21	Eingeleitet	Jefferies	Buy
2024-10-10	Fortgesetzt	Raymond James	Outperform
2024-07-29	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2024-06-26	Herabstufung	Citigroup	Buy → Neutral
2024-05-31	Eingeleitet	Piper Sandler	Overweight
2024-05-28	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2024-05-14	Hochstufung	Oppenheimer	Perform → Outperform
2024-01-31	Eingeleitet	BMO Capital Markets	Outperform
2023-12-13	Fortgesetzt	Citigroup	Buy
2023-12-12	Eingeleitet	Deutsche Bank	Buy
2023-11-21	Eingeleitet	Wedbush	Outperform
2023-10-31	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2023-10-31	Herabstufung	Oppenheimer	Outperform → Perform
2023-06-23	Herabstufung	Evercore ISI	Outperform → In-line
2023-04-26	Eingeleitet	SMBC Nikko	Outperform
2023-04-04	Eingeleitet	Citigroup	Buy
2023-03-01	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2022-12-22	Bestätigt	BTIG Research	Buy
2022-12-16	Hochstufung	UBS	Neutral → Buy
2022-04-04	Fortgesetzt	Cantor Fitzgerald	Overweight
2022-01-05	Bestätigt	Needham	Buy
2021-12-09	Hochstufung	Oppenheimer	Perform → Outperform
2021-11-05	Hochstufung	JP Morgan	Neutral → Overweight
2021-09-15	Hochstufung	Guggenheim	Neutral → Buy
2021-08-05	Hochstufung	JP Morgan	Underweight → Neutral
2021-06-15	Eingeleitet	BTIG Research	Buy
2021-04-26	Fortgesetzt	Credit Suisse	Neutral
2021-01-12	Herabstufung	Citigroup	Buy → Neutral
2021-01-11	Herabstufung	UBS	Buy → Neutral
2021-01-08	Herabstufung	JP Morgan	Overweight → Underweight
2021-01-08	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-01-08	Herabstufung	Raymond James	Outperform → Mkt Perform
2020-11-11	Eingeleitet	Berenberg	Hold
2020-10-28	Eingeleitet	UBS	Buy
2020-08-25	Eingeleitet	Raymond James	Outperform
2020-08-20	Herabstufung	Credit Suisse	Outperform → Neutral
2020-03-31	Eingeleitet	Mizuho	Buy
2019-11-01	Eingeleitet	Guggenheim	Buy
2019-08-21	Bestätigt	Needham	Buy
2019-07-09	Bestätigt	Morgan Stanley	Overweight
2019-07-01	Bestätigt	RBC Capital Mkts	Outperform
2019-04-12	Eingeleitet	Evercore ISI	Outperform
2019-03-11	Bestätigt	Credit Suisse	Outperform
2018-10-12	Eingeleitet	Bernstein	Outperform
2018-10-01	Eingeleitet	Cantor Fitzgerald	Overweight
2018-09-26	Bestätigt	RBC Capital Mkts	Outperform
2018-09-14	Fortgesetzt	BofA/Merrill	Buy
2018-09-06	Eingeleitet	Credit Suisse	Outperform
2018-08-01	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2018-06-21	Bestätigt	Robert W. Baird	Outperform
2018-06-20	Bestätigt	Needham	Buy
2018-06-19	Bestätigt	H.C. Wainwright	Buy

Alle ansehen

Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten

Aug 16, 2026

Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

Aug 16, 2026

Aug 15, 2026

SRPT6155802 Latest News and Headlines - TradingView

Aug 15, 2026

Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits

Aug 15, 2026

Aug 14, 2026

Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to "Hold" at Zacks Research - marketbeat.com

Aug 14, 2026

Sarepta Therapeutics (SRPT) submits Form 13F showing one entry and $0 value - Stock Titan

Aug 14, 2026

Massachusetts Biotech's Flagship Gene Therapy Posts Fifth Straight Quarterly Decline as Muscular Dystrophy Data Loom - Streetwise Reports

Aug 14, 2026

Aug 13, 2026

Sarepta Therapeutics (SRPT) sees 5.05% ownership reported by AQR in 13G/A - Stock Titan

Aug 13, 2026

Bank of America Corp DE Increases Stock Position in Sarepta Therapeutics, Inc. $SRPT - marketbeat.com

Aug 13, 2026

SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits

Aug 12, 2026

Assenagon Asset Management S.A. Makes New $8.16 Million Investment in Sarepta Therapeutics, Inc. $SRPT - marketbeat.com

Aug 12, 2026

Aug 11, 2026

SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - Stocktwits

Aug 11, 2026

Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits

Aug 11, 2026

Dimensional Fund Advisors LP Sells 121,412 Shares of Sarepta Therapeutics, Inc. $SRPT - marketbeat.com

Aug 11, 2026

Aug 10, 2026

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - The National Law Review

Aug 10, 2026